The antidiabetic drug teneligliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor with a thiazolidine-specific structure. This study aimed to investigate whether teneligliptin can activate PPARγ directly and/or indirectly in cell-based assays.
Introduction
PPARγ, a member of the peroxisome proliferatoractivated receptor (PPAR) subfamily of ligand-dependent nuclear receptors 1, 2 , plays a dominant role in adipose cell Only teneligliptin has a thiazolidine-like structure among the DPP-4 inhibitors administered to help manage T2DM 11 . Since teneligliptin is functionally and structurally similar to TZDs, we investigated whether teneligliptin can activate PPARγ in cell-based assays.
Materials and Methods

Chemicals
Teneligliptin powder was donated by Mitsubishi Tanabe Pharma. Rosiglitazone, pioglitazone and GW9662
were purchased from Sigma-Aldrich. Teneligliptin was dissolved in distilled water to prepare a 10-mM stock solution. Rosiglitazone and pioglitazone were dissolved in ethanol. GW9662 was dissolved in DMSO. Polyethylenimine MAX (PEI MAX ) 12 (Polysciences Inc.) was dissolved in distilled water to a final concentration of 1 mg/ mL. The pH was adjusted to 7.0 with 1 N NaOH.
Plasmid Constructs
Oligonucleotides PPRE_UP_MluI-BglII, 5'-cgcgtgacgTG GGTCAAAGGTCAttcagtcgaca-3' and PPRE_LP_MluI-BglII, 5 ' -GATCtgtcgactgaaTGACCTTTGACCCAcgtca-3 '
were annealed to prepare a double-stranded DNA fragment containing the single PPARγ response element (PPRE, upper case) (Fig. 1A) . The PPRE fragment was inserted into the Bgl II site of the pGL3-Promoter vector (Promega) to generate a PPARγ-responsive luciferase reporter construct, designated pGL3-Promoter-PPRE (Fig. 1   B) . We overexpressed PPARγ2 without an epitope tag using a cDNA clone (MC201042) harboring full-length mouse Pparγ2 cDNA in pCMV6-Kan/Neo (OriGene).
Other cDNAs encoding mouse RXRα, PGC-1α, PGC-1β, PGC-2, SRC1, SRC3 and p300 were amplified from a 3T3-L1 cDNA library using appropriate primer sets ( Table 1) .
The PCR products were inserted into the expression vec- 
Results
Effects of Teneligliptin on PPRE-Reporter Activity
Since teneligliptin is functionally and structurally similar to TZDs, we investigated whether teneligliptin can affect transcriptional activity of PPARγ using cell-based reporter assays. We co-transfected a reporter construct containing 1xPPRE (Fig. 1A) with a mouse PPARγ2 overexpression vector and the PPARγ-associated transcription factors, RXRα and CBP, into NIH3T3 cells. The nucleotide sequence of PPRE was determined based on previous reports 3,13 16 . Luciferase activity was measured after a 3-day incubation with various concentrations of teneligliptin. Relative luciferase activity increased dosedependently in the presence of teneligliptin (Fig. 1B) .
Teneligliptin significantly activated PPRE-reporter expression at 50 and 100 (data not shown) μM. Relative luciferase activity did not significantly increase in negative control cells without PPARγ2 overexpression even in the presence of 50 μM teneligliptin (Fig. 1B) . Thus, Fig. 1 teneligliptin appeared to activate PPRE-regulated expression although the dose exceeded that of TZDs (nanomolar range) and the concentration of teneligliptin used in the clinical therapy (submicromolar range).
Effect of Transcription Coregulators on TeneligliptinInduced Transactivation of PPRE-Reporter Construct
PPARγ activity is regulated by many common transcription coregulators including the nuclear receptors CBP/p300, SRC1 and PGC-1α. To determine whether these coregulators modify the transactivation of PPREreporter expression induced by teneligliptin, we cotransfected a coregulator expression vector with a reporter and PPARγ2 expression constructs. Figure 2A shows that 10 and 50 μM teneligliptin increased PPREreporter activity in the cells that overexpressed only PPARγ2 (pcDNA, empty vector)(p<0.01). The activation effect of teneligliptin was lost in cells overexpressing PGC-1α, PGC-1β, PGC-2 or CREBP; reporter activity did not significantly differ between 0 and 50 μM. The overexpression of SRC1, SRC3 and p300 caused a similar Table 1 Primer sequences of transcription factors
5'-CAGGCTCCGCCGCTCAGCCGGTGATG-3' Fig. 2 A, Effects of transcription coregulators on transactivation of PPRE-reporter construct. A luciferase reporter construct containing 1xPPRE was co-transfected with constructs that express PPARγ2 and transcription coregulators such as PGC1α or SRC1. Adding teneligliptin into culture medium at 10 or 50 μM of positive-control cells overexpressing only PPARγ2 resulted in a significant activation of reporter gene expression (pcDNA, empty vector), whereas suppression or no effect on transactivation was found in cells overexpressing either transcription coregulators (n=4). *P<0.01, **P<0.05. B, Effects of GW9662, PPARγ antagonist, on PPRE-reporter transactivation induced by teneligliptin. GW9662 (1 10 μM) did not affect PPRE-reporter transactivation induced by teneligliptin (10 and 50 μM) (n=8). *P<0.01.
amount of reporter gene upregulation at only 50 μM compared with that of untreated control cells. Thus, transcription coregulators used here slightly suppressed or did not affect the reporter gene upregulation by teneligliptin. Fig. 3 Effects of teneligliptin on adipogenesis of ST2 cells. Teneligliptin (1.56 and 12.5 μM) did not induce or rather slightly suppressed adipogenesis. Adipogenesis is evident in cells cultured in medium containing the PPARγ agonist ligands rosiglitazone or pioglitazone, compared with that of cells cultured in medium containing no agonist (n=8). *P<0.01.
Effect of PPARγ Antagonist, GW9662, on Transactivation of PPRE-Reporter Construct by Teneligliptin
The activity of the ligand-dependent transcription fac- 
Effect of Teneligliptin on Adipogenesis
The finding that teneligliptin stimulated PPRE-reporter transactivation in NIH3T3 cells indicated that it is a potential PPARγ activator. During the adipocyte differentiation, PPARγ is upregulated and plays a pivotal role in the adipogenic signaling cascade 18, 19 . (Fig. 3) .
Discussion
Teneligliptin is a DPP-4 inhibitor that is administered to patients with T2DM to control fasting and postprandial glucose levels. Teneligliptin also prevents obesity and obesity-related manifestations in mice with obesity induced by a high-fat diet 21 . One of the main reasons for this might be increased energy expenditure because the total O2 consumption was increased by 22% in mice dosed with teneligliptin and fed with a high-fat diet.
Teneligliptin could not increase the expression levels of receptors that increase energy expenditure such as PPARs, estrogen receptors, and thyroid receptors 21 . The present study found that teneligliptin can affect genes that are regulated by PPARγ-binding to PPREs (Fig. 1B) 25 27 and UCP-3 in muscle 28 .
This might be a unique feature of teneligliptin as it has not been identified in other DPP-IV inhibitors such as sitagliptin and linagliptin.
Teneligliptin did not promote but rather suppressed the adipogenesis of ST2 cells (Fig. 3) . Teneligliptin decreases uric acid secretion in rats fed with a high-fat diet and in 3T3-L1 adipocytes by reducing xanthine dehydrogenase (XDH) activity 29 . The activity of XDH is transiently induced during the 3T3-L1-cell differentiation into adipocytes 30 . Furthermore, knockdown of xanthine oxidoreductase, which has the enzymatic activity of either XDH or xanthine oxidase, causes a decrease in uric acid levels and consequently inhibits the mRNA-upregulation and transcriptional activity of PPARγ during adipogenesis 30 . Therefore, the suppression of ST2-cell differentiation into adipocytes might be due to reduced activity of XDH caused by teneligliptin, although PPARγ, which is essential to the initiation of adipogenesis, was probably partially activated by an association between teneligliptin and a non-ligand-binding domain of PPARγ.
In conclusion, we found that teneligliptin could increase PPARγ activity in cell-based assays irrespective of the PPARγ ligand-binding domain, whereas it inhibits adipocyte differentiation.
